Ginkgo biloba for tinnitus by Sereda, Magdalena et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Ginkgo biloba for tinnitus
Author(s) Sereda, Magdalena; Xia, Jun; Scutt, Polly; Hilton, Malcolm P.; El
Refaie, Amr; Hoare, Derek J.
Publication date 2019-12
Original citation Sereda, M., Xia, J., Scutt, P., Hilton, M. P., El Refaie, A. and Hoare, D.
J. (2019) 'Ginkgo biloba for tinnitus', Cochrane Database of Systematic
Reviews 2019, 12, CD0135141 (15pp). doi:
10.1002/14651858.CD013514




Access to the full text of the published version may require a
subscription.
Rights © 2019, The Cochrane Collaboration. Published by John Wiley &








Cochrane Database of Systematic Reviews
 
Ginkgo biloba for tinnitus (Protocol)
 
  Sereda M, Xia J, Scutt P, Hilton MP, El Refaie A, Hoare DJ  
  Sereda M, Xia J, Scutt P, Hilton MP, El Refaie A, Hoare DJ. 
Ginkgo biloba for tinnitus. 




Ginkgo biloba for tinnitus (Protocol)
 








Cochrane Database of Systematic Reviews










CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 15
DECLARATIONS OF INTEREST..................................................................................................................................................................... 15
SOURCES OF SUPPORT............................................................................................................................................................................... 15
Ginkgo biloba for tinnitus (Protocol)









Cochrane Database of Systematic Reviews
[Intervention Protocol]
Ginkgo biloba for tinnitus
Magdalena Sereda1, Jun Xia2, Polly Scutt1, Malcolm P Hilton3, Amr El Refaie4, Derek J Hoare1
1NIHR Nottingham Biomedical Research Centre, Division of Clinical Neuroscience, School of Medicine, University of Nottingham,
Nottingham, UK. 2Nottingham China Health Institute, The University of Nottingham Ningbo, Ningbo, China. 3ENT Department, Royal
Devon and Exeter NHS Trust, Exeter, UK. 4Department of Speech and Hearing Sciences, University College Cork, Cork, Ireland
Contact address: Magdalena Sereda, NIHR Nottingham Biomedical Research Centre, Division of Clinical Neuroscience,
School of Medicine, University of Nottingham, Ropewalk House, 113 The Ropewalk, Nottingham, NG1 5DU, UK.
magdalena.sereda@nottingham.ac.uk.
Editorial group: Cochrane ENT Group.
Publication status and date: New, published in Issue 12, 2019.
Citation:  Sereda M, Xia J, Scutt P, Hilton MP, El Refaie A, Hoare DJ. Ginkgo biloba for tinnitus. Cochrane Database of Systematic Reviews
2019, Issue 12. Art. No.: CD013514. DOI: 10.1002/14651858.CD013514.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the eEects of Ginkgo biloba for tinnitus in adults and children.
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B A C K G R O U N D
This is a new protocol for a review that will supersede the Cochrane
Review 'Ginkgo biloba for tinnitus', which was first published in the
Cochrane Library in Issue 3, 2013. The following paragraphs and
Description of the condition are based on the Cochrane Review
'Amplification with hearing aids for patients with tinnitus and co-
existing hearing loss' and are reproduced with permission (Hoare
2014). Description of the intervention and How the intervention
might work are based on the Cochrane Review 'Ginkgo biloba for
tinnitus' and are reproduced with permission (Hilton 2013).
Tinnitus is defined as the perception of sound in the absence of an
external source (JastreboE 2004). It is typically described by those
who experience it as a ringing, hissing, buzzing or whooshing sound
and is thought to result from abnormal neural activity at some point
or points in the auditory pathway, which is erroneously interpreted
by the brain as sound. Tinnitus can be either objective or subjective.
Objective tinnitus refers to the perception of sound that can be
also heard by the examiner and is usually due to turbulent blood
flow or muscular contraction (Roberts 2010). Most commonly,
however, tinnitus is subjective; the sound is only heard by the
person experiencing it and no source of the sound is identified
(JastreboE 1988).
Tinnitus aEects between 5% and 43% of the general population
and prevalence increases with age (McCormack 2016). It can be
experienced acutely, recovering spontaneously within minutes
to weeks, but is considered chronic and unlikely to resolve
spontaneously when experienced for more than three months
(Gallus 2015; Hall 2011).
For many people tinnitus is persistent and troublesome, and
has disabling eEects such as insomnia, diEiculty concentrating,
diEiculties in communication and social interaction, and negative
emotional responses such as anxiety and depression (Hall 2018).
In approximately 90% of cases, chronic tinnitus is co-morbid with
some degree of measurable hearing loss, which may confound
these disabling eEects (Fowler 1944; Sanchez 2002). Nevertheless,
the association between hearing loss and tinnitus is not simple
or straightforward; not all people with hearing loss experience
tinnitus, and conversely some people with clinically normal hearing
have tinnitus (Baguley 2013). It has been reported that 40% of
patients are unable to identify what health condition is associated
with their tinnitus onset, i.e. the tinnitus is idiopathic (Henry 2005).
An important implication in clinical research is that outcome
measures need to distinguish benefits specific to improved hearing
from those specific to improvement in the psychological aspects of
tinnitus.
Description of the condition
Diagnosis and clinical management of tinnitus
There is no standard procedure for the diagnosis or management
of tinnitus. Practice guidelines and the approaches described
in studies of usual clinical practice typically reflect diEerences
between the clinical specialisms of the authors or diEerences in
the clinical specialisms charged with meeting tinnitus patients'
needs (medical, audiology/hearing therapy, clinical psychology,
psychiatry), or the available resources of a particular country or
region (access to clinicians or devices, for example) (Biesinger 2010;
Cima 2012; Department of Health 2009; Hall 2011; Henry 2008;
Hoare 2011). Common across all these documents, however, is the
use or recommendation of written questionnaires to assess tinnitus
and its impact on patients and their families by measuring tinnitus
symptom severity (e.g. impact of tinnitus on quality of life, activities
of daily living or sleep), and a judgement about patients who
are experiencing a degree of psychological distress (depression or
anxiety). Assessment of the perceptual characteristics of tinnitus
(pitch, loudness, minimum masking level) and residual inhibition
are also recommended (Cima 2019). Although these measures do
not correlate well with tinnitus symptom severity (Hiller 2006), they
can prove useful in patient counselling (Henry 2004), as a baseline
before start of treatment (El Refaie 2004), or by demonstrating
stability of the tinnitus percept over time (Department of Health
2009).
Clinical management strategies include education and advice,
relaxation therapy, tinnitus retraining therapy (TRT), cognitive
behavioural therapy (CBT), sound enrichment using ear-level
sound generators or hearing aids, and drug therapies to manage
co-morbid symptoms such as insomnia, anxiety or depression (for
example, Department of Health 2009; Tunkel 2014). As yet, no
drug has been approved for tinnitus by a regulatory body (e.g. the
European Medicines Agency or US Food and Drug Administration).
Pathophysiology
Most people with chronic tinnitus have some degree of measurable
hearing loss (Ratnayake 2009), and the prevalence of tinnitus
increases with greater hearing loss (Han 2009; Martines 2010). The
varying theories of tinnitus generation involve changes in either
function or activity of the peripheral (cochlea and auditory nerve) or
central auditory nervous systems (Henry 2005). Theories involving
the peripheral systems include the discordant damage theory,
which predicts that the loss of outer hair cell function, where inner
hair cell function is leK intact, leads to a release from inhibition
of inner hair cells and aberrant activity (typically hyperactivity)
in the auditory nerve (JastreboE 1990). Such aberrant auditory
nerve activity can also have a biochemical basis, resulting from
excitotoxicity or stress-induced enhancement of inner hair cell
glutamate release with upregulation of N-methyl-D-aspartate
(NMDA) receptors (Guitton 2003; Sahley 2001).
In the central auditory system, structures implicated as possible
sites of tinnitus generation include the dorsal cochlear nucleus
(Middleton 2011; Pilati 2012), the inferior colliculus (Dong
2010; Mulders 2010), and the auditory and non-auditory cortex
(discussed further below). There is a strong rationale that tinnitus
is a direct consequence of maladaptive neuroplastic responses
to hearing loss (Moller 2000; Muhlnickel 1998). This process
is triggered by sensory deaEerentation and a release from
lateral inhibition in the central auditory system allowing irregular
spontaneous hyperactivity within the central neuronal networks
involved in sound processing (Eggermont 2004; Rauschecker 1999;
Seki 2003). As a consequence of this hyperactivity, a further
physiological change noted in tinnitus patients is increased
spontaneous synchronous activity occurring at the subcortical and
cortical level, measurable using electroencephalography (EEG) or
magnetoencephalography (MEG) (Dietrich 2001; Tass 2012; Weisz
2005). Another physiological change thought to be involved in
tinnitus generation is a process of functional reorganisation, which
amounts to a change in the response properties of neurons within
the primary auditory cortex to external sounds. This eEect is well
demonstrated physiologically in animal models of hearing loss
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(Engineer 2011; Norena 2005). Evidence in humans, however, is
limited to behavioural evidence of cortical reorganisation aKer
hearing loss, demonstrating improved frequency discrimination
ability at the audiometric edge (Kluk 2006; McDermott 1998; Moore
2009; Thai-Van 2002; Thai-Van 2003), although Buss 1998 did not
find this eEect. For comprehensive reviews of these physiological
models, see Adjamian 2009 and Norena 2011.
It is also proposed that spontaneous hyperactivity could cause an
increase in sensitivity or 'gain' at the level of the cortex, whereby
neural sensitivity adapts to the reduced sensory inputs, in eEect
stabilising mean firing and neural coding eEiciency (Norena 2011;
Schaette 2006; Schaette 2011). Such adaptive changes would be
achieved at the cost of amplifying 'neural noise' due to the overall
increase in sensitivity, ultimately resulting in the generation of
tinnitus.
Increasingly, non-auditory areas of the brain, particularly areas
associated with emotional processing, are also implicated in
bothersome tinnitus (Rauschecker 2010; Vanneste 2012). Vanneste
2012 describes tinnitus as "an emergent property of multiple
parallel dynamically changing and partially overlapping sub-
networks", implicating the involvement of many structures
of the brain more associated with memory and emotional
processing in tinnitus generation. However, identification of the
structural components of individual neural networks responsible
for either tinnitus generation or tinnitus intrusiveness, which
are independent of those for hearing loss, remains open to
future research (Melcher 2013). One further complication in
understanding the pathophysiology of tinnitus is that not all people
with hearing loss have tinnitus and not all people with tinnitus
have a clinically significant and measurable hearing loss. Other
variables, such as the profile of a person's hearing loss, may
account for diEerences in their tinnitus report. For example, König
2006 found that the maximum slope within audiograms was higher
in people with tinnitus than in people with hearing loss who do not
have tinnitus, despite the 'non-tinnitus' group having the greater
mean hearing loss. This suggests that a contrast in sensory inputs
between regions of normal and elevated threshold may be more
likely to result in tinnitus. However, this finding is not consistent
across the literature (Sereda 2011; Sereda 2015).
Description of the intervention
Extracts of Ginkgo biloba leaves have been used for medicinal
purposes for at least 5000 years in China, where they form an
important component of the traditional Chinese pharmacopoeia (a
book which lists drugs and instructions for their use). More recently
Ginkgo biloba extracts have been used in Western countries. In
the USA, Canada and the UK extracts are widely available as non-
prescription food supplements (Diamond 2013; Mei 2017; Ude
2013). In France and Germany a standardised dry leaf extract is
registered as a drug and is commonly prescribed for tinnitus (Hall
2011; Ude 2013). However, there are several components in the
available Gingko biloba preparations. A purified and enriched liquid
extract is prepared from dried leaves of the maidenhair plant. The
liquid extract is dried to give one part extract from 50 raw leaves.
The most important active chemical compounds are flavonoids
(ginkgo-flavone glycosides) and terpenoids (ginkgolides A, B, C,
J and bilobalide). Ginkgolides appear to be unique to Ginkgo
biloba and have not been isolated from any other plant species.
Standardised Ginkgo leaf extracts have been used in clinical trials
for tinnitus, and cognitive and cardiovascular disorders, at daily
doses of 60 mg to 450 mg (Mei 2017; Yang 2011). These preparations
contain standardised amounts of the above compounds. EGb761
(Tebonin, Tanakan, Rökan) contains 24% ginkgo-flavone glycosides
and 6% terpenoids, and LI 1370 (Kaveri) contains 25% ginkgo
flavone glycosides and 6% terpenoids (Blumenthal 1998; Mei
2017). Although the quantities are standardised, the manufacturing
process is diEerent and the ratio of active ingredients within each
sub-class may be diEerent. There is no standardisation for food
supplement preparations (Mei 2017).
The most commonly reported side eEect of Ginkgo biloba is mild
gastrointestinal disturbance (e.g. stomach pain, change in bowel
habit). Serious side eEects are rare, but include bleeding problems,
interaction with anticoagulant medication and seizures (Ernst 2002;
Mei 2017; Rajarajan 2018).
How the intervention might work
Several mechanisms of action of Ginkgo biloba have been proposed
in the light of its many active ingredients. Human, animal and in
vitro studies indicate the following eEects:
• A vasoregulatory eEect (altering the tone of blood vessels)
promoting increased blood flow (Diamond 2013; Lichota 2019;
Nuhu 2014; Shu 2019; Xia 2007; Zhou 2004). Animal and human
studies have shown that Ginkgo biloba can increase skin
(Boelsma 2004; Jung 1990; Koltinger 1989), cardiac (Xiao 2019)
and cerebral blood flow (Li 2018; Mashayekh 2011).
• Antagonism of platelet activating factor (PAF) (Diamond 2013;
Nash 2015; Xia 2007; Zhou 2004). This eEect is specific to the
ginkgolides (predominantly B). PAF causes platelet (a blood
constituent involved in blood clot formation) aggregation,
neutrophil degranulation (activation of immune cells within
the blood stream) and oxygen radical production. Ginkgolides
appear to protect against the eEects of hypoxic brain injury
from cerebral ischaemia (permanent brain damage caused by
insuEicient blood and oxygen supply) in laboratory animals
(Braquet 1991; DeFeudis 1991; Li 2018; Smith 1996) and humans
(Oskouei 2013).
• Antioxidant activity including scavenging of free radicals,
indirectly inhibiting formation of free radicals, regulation of
oxidative stress and anti-lipid peroxidation (Lichota 2019;
Mahadevan 2008; Singh 2019; Zhou 2004; Zuo 2017).
• Changes in the metabolism of neurons (Blecharz-Klin 2009;
DeFeudis 2000; Eckert 2005) and restoration of age-related
deficiencies in central neurotransmitter systems (Blecharz-Klin
2009; DeFeudis 2000; Fehske 2009).
• Enhancement of neuronal plasticity including increased
long-term potentiation, spine density, neuritogenesis and
neurogenesis, as shown in pre-clinical reports (Müller 2012).
• Anti-inflammatory eEects and protective actions against brain
damage, possibly through its terpenoids and ginkgolides (Cheng
2003; Lichota 2019; Nuhu 2014; Shu 2019; Xia 2007; Zhang 2016).
The Ginkgo biloba leaf extract has been shown to reduce the
level of cytokines and inflammatory factors such as tumour
necrosis factor alpha (TNF-α), interleukin 6 (Il-6), interleukin 1
beta (Il 1-β) and matrix metalloproteinase 9 (Omidkhoda 2019;
Zhang 2016).
These mechanisms may treat tinnitus by preventing free-radical
damage to the cochlea, or increasing blood flow, improving the
health of the inner ear (Didier 1996; Smith 2013). Tziridis 2014
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tested the eEectiveness of prophylactic treatment with EGb 761
for noise-induced hearing loss and development of tinnitus aKer
noise trauma in an animal model. Based on the results they
suggested significant neuroplastic eEects of EGb 761 on auditory
processing at the peripheral and central level of the auditory
pathway as measured with behavioural and electrophysiological
approaches. They proposed a model of the eEects of EGb 761
on auditory processing with two main eEects: 1) an increase in
auditory brainstem activity leading to an increased thalamic input
to the primary auditory cortex; and 2) an asymmetric eEect on
lateral inhibition in the primary auditory cortex.
A study by Krauss 2016 examined the therapeutic eEects of EGb
761 aKer the formation of permanent noise-induced hearing loss
and tinnitus in an animal model. They found that treatment
with EGb 761 led to recovery of auditory thresholds and
reduced behavioural signs of tinnitus. Interestingly, while the
auditory thresholds were maintained, behavioural signs of tinnitus
reappeared aKer discontinuation of treatment. An analysis of
the auditory brainstem responses (ABRs) showed changes in
ABR wave amplitude and latency at diEerent levels of the
auditory pathway (increase of response to low stimulus intensities
and decrease at high intensities) rather than restoration of the
auditory processing back to pre-trauma conditions. Based on
that result, the authors suggested a global inhibitory mechanism
that counteracts tinnitus. The EGb 761 extract was also shown
to protect against noise-induced hearing loss by inhibiting the
expression of proinflammatory cytokines and cyclooxygenase 2
(COX-2), and increasing values of heat shock proteins in the
rat cochlea (Dogan 2018). It was also shown to protect against
cisplatin- and gentamicin-induced hair cell loss, and subsequent
changes in brain activity in animal models (Huang 2007; Yang 2011).
Why it is important to do this review
In England alone there are an estimated ¾ million general practice
consultations every year where the primary complaint is tinnitus (El
Shunnar 2011), equating to a major burden on healthcare services.
Use of Gingko biloba for tinnitus is currently recommended
against in the European tinnitus guideline (Cima 2019) and the
American Academy of Otolaryngology Clinical Practice Guideline
(Tunkel 2014). Both guidelines conclude that there is no proven
eEicacy of Gingko biloba and that there is potential for harm.
There is evidence that Ginkgo biloba interacts with antithrombotic
drugs to cause serious bleeding and increases bleeding risk in
clotting disorders (Posadzki 2013). A worldwide survey of dietary
supplements used to treat tinnitus reported that Ginkgo biloba was
the most cited supplement resulting in adverse eEects (diarrhoea,
nausea, hearing, dizziness, headache, bleeding, blood pressure
changes, chest pain, palpitation and increased urination) (Coelho
2016). Despite this, Ginkgo biloba is the most commonly used
herbal supplement for tinnitus (Hall 2011). A survey of treatment
options for subjective tinnitus showed that Ginkgo biloba was
a popular first-line treatment prescribed by general practitioners
(GPs) and ENT physicians across Europe, with a proportion of
patients prescribed Ginkgo biloba as high as 71% in some countries
(Hall 2011). Ginkgo biloba is freely available for purchase in health
food stores across Europe and America (Chan 2007). A recent survey
showed that 1 in 10 people with tinnitus in the UK use alternative
therapies, including Gingko biloba (McFerran 2018).
The previous Cochrane Review on this question concluded that
there was no evidence that Gingko biloba was eEective in patients
with a primary complaint of tinnitus (Hilton 2013). However, the
methods and searches used in that review now require updating.
O B J E C T I V E S
To assess the eEects of Ginkgo biloba for tinnitus in adults and
children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies with following design characteristics:
• randomised controlled trials, including cluster-randomised
(cross-over trials will be eligible if data from before the cross-
over can be extracted, to avoid the potential for a carry-over
phenomenon).
We will exclude studies with the following design characteristics:
• quasi-randomised controlled studies.
We will apply no restrictions on language, year of publication or
publication status.
Types of participants
Adults and children with acute (≤ 3 months) or chronic (> 3 months)
subjective idiopathic tinnitus.
Types of interventions
The review will include all courses of Ginkgo biloba, regardless of
dose regimens or formulations and for any duration of treatment.
The main comparison will be:
• Ginkgo biloba versus placebo.
Other possible comparison pairs include:
• Ginkgo biloba versus no intervention;
• Ginkgo biloba versus education and information only.
Concurrent use of other medication or other treatment will be
acceptable if used equally in each group. For example, Ginkgo
biloba with an additional intervention versus placebo with an
identical intervention. Where an additional intervention was used
equally in both groups, we will analyse this as a separate
comparison.
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
Primary outcomes
• Tinnitus symptom severity (such as the impact of tinnitus on
quality of life, activities of daily living and sleep), as measured
by the global score on a multi-item tinnitus questionnaire (Table
1). These include:
• Tinnitus Questionnaire (Hallam 1996; Hiller 1992);
• Tinnitus Functional Index (Meikle 2012);
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• Tinnitus Handicap Inventory (Newman 1996);
• Tinnitus Handicap Questionnaire (Kuk 1990);
• Tinnitus Reaction Questionnaire (Wilson 1991);
• Tinnitus Severity Scale (Sweetow 1990).
We will update this list on an ongoing basis whenever other
questionnaires are introduced.
• Significant adverse eEect: bleeding, seizures.
Secondary outcomes
• Tinnitus loudness (a change in subjective perception) measured
using either patient-reported instruments (including visual
analogue scales or numerical rating scales) or performance-
based procedures (including tinnitus loudness matching or
minimum masking level).
• Tinnitus intrusiveness measured using a self-report multi-item
questionnaire or validated subscale (Hall 2018a).
• Generalised depression as measured by validated
questionnaires, such as the Beck Depression Inventory II
(Beck 1996), the depression scale of the Hospital Anxiety and
Depression Scale (HADS; Zigmond 1983), and the Hamilton
Rating Scale for Depression (Hamilton 1960).
• Generalised anxiety as measured by a validated scale, for
example the anxiety scale of the HADS or Beck Anxiety Inventory
(Beck 1988) or the Anxiety Sensitivity Index (Reiss 1986).
• Health-related quality of life as measured by a validated scale,
for example, the Short-Form 36 (Hays 1993), WHOQoLBREF
(Skevington 2004), and other WHOQoL versions, and the Health
Utilities Index (Furlong 2001).
• Other adverse eEects: gastrointestinal upset, headache, allergic
reaction.
We will assess outcomes as short-term (less than three months)
and long-term (three to six months). We will also consider whether
these outcomes are sustained beyond six months.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct systematic
searches for randomised controlled trials and controlled clinical
trials. There will be no language, publication year or publication
status restrictions. We may contact original authors for clarification
and further data if trial reports are unclear and we will arrange
translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane ENT Register (search via the Cochrane Register of
Studies to date);
• the Cochrane Central Register of Controlled Trials (CENTRAL)
(search via the Cochrane Register of Studies to date);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to date);
• Ovid EMBASE (1974 to date);
• Ovid AMED (1985 to date);
• Web of Science, Web of Science (1945 to date);
• EBSCO CINAHL (1982 to date);
• LILACS (Latin American and Caribbean Health Science
Information database), lilacs.bvsalud.org (search to date);
• CNKI, www.cnki.com.cn (searched via Google Scholar 1999 to
date);
• ClinicalTrials.gov, (search via the Cochrane Register of Studies
and clinicaltrials.gov to date);
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (search via the Cochrane Register of
Studies and www.who.int/ictrp to date).
The subject strategies for databases will be modelled on the search
strategies designed for CENTRAL, MEDLINE and Embase (Appendix
1). There are likely to be low numbers of search results therefore an
RCT filter will not be applied.
Searching other resources
We will scan the reference lists of identified publications for
additional trials and contact trial authors if necessary. In addition,
the Information Specialist will search Ovid MEDLINE to retrieve
existing systematic reviews relevant to this systematic review, so
that we can scan their reference lists for additional trials. The
Information Specialist will also run non-systematic searches of
Google Scholar to retrieve grey literature and other sources of
potential trials.
We will not perform a separate search for adverse eEects. We will
consider adverse eEects described in included studies only.
Data collection and analysis
Selection of studies
Two authors (MS, MH, AER, DJH) will independently review all
records retrieved to determine their eligibility for inclusion in the
review. The authors will then review the full-text articles of the
retrieved studies and independently apply the inclusion criteria.
Any disagreements will be discussed, involving a third author if
necessary until a consensus is reached.
Data extraction and management
Two authors (MS, MH, AER, JX, DJH) will independently extract data
using a purposely designed data extraction form. We will pilot the
data extraction form on a subset of articles and revise it if indicated
before formal data extraction begins. Where necessary, or where
insuEicient data are provided for the study, we will contact the
study authors for further information.
Information to be extracted will include: study design, setting,
methods or randomisation and blinding, power, inclusion and
exclusion criteria, type of intervention and control, treatment
duration, treatment fidelity, type and duration of follow-up,
outcome measures used and statistical tests performed.
Data to be extracted will include: baseline characteristics of
participants (age, sex, duration of tinnitus, tinnitus symptom
severity, tinnitus loudness estimates, details of co-morbid hearing
loss, anxiety or depression), details of any attrition or exclusion,
group mean and standard deviation for outcome measures at pre-
and post-intervention and follow-up, and results of any statistical
between-group comparisons.
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We will contact authors where further information is required that
is not contained within the study publication or in an accessible
database. If not reported or provided by the authors, we will
estimate standard deviations in RevMan 5.3 (RevMan 2014) using
the available data, such as standard errors, confidence intervals, P
values and t values. Where data are only available in graph form, we
will make and agree numeric estimates.
AKer independent data extraction by two authors, we will review
the extracted data for disagreements, and revisit and discuss the
relevant studies as required to reach a final consensus.
Assessment of risk of bias in included studies
Two authors (MS, MH, AER, JX, DJH) will undertake assessment
of the risk of bias of the included trials independently, with the
following taken into consideration, as guided by the Cochrane





• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We will use the Cochrane 'Risk of bias' tool in RevMan 5.3 (RevMan
2014), which involves describing each of these domains as reported
in the trial and then assigning a judgement about the adequacy
of each entry: 'low', 'high' or 'unclear' risk of bias. We will resolve
diEerences of opinion by discussion. If no consensus is reached, we
will consult a third author to adjudicate.
Measures of treatment e8ect
We will analyse dichotomous data as risk ratios (RR) with 95%
confidence intervals (CIs). We will summarise continuous outcomes
as mean diEerences (MD) with 95% CI. We will use standardised
mean diEerences (SMD) (Cohen's d eEect size (ES)) when diEerent
scales of measurement have been used to measure the same
outcome. A positive ES indicates that the treatment group achieved
better outcomes than the control group.
Unit of analysis issues
For parallel-group RCTs the unit of analysis will be the group
mean. However, some studies included in the review may involve
clustering or compare more than two intervention groups. To
avoid unit of analysis errors we will consider alternative analyses
for cluster-randomised trials and for studies with more than two
intervention groups. For cluster-randomised trials we will adopt
approximate analyses - eEective sample sizes (Donner 2002). For
studies with more than two intervention groups, we will either
combine groups to create a single pair-wise comparison or, if this is
not appropriate, select the most relevant pair of interventions for
comparison.
Dealing with missing data
Where necessary and where suEicient data from the study
are not provided, we will contact the authors of the study
requesting further details about missing data and reasons for
the incompleteness of the data. If no response is obtained, we
will impute data if we judge the data to be 'missing at random'.
If we judge data to be 'missing not at random', the missing
data may aEect the overall results; we will therefore not impute
data. In the latter case, we will conduct sensitivity analyses with
diEerent assumptions. We will be alert to potential mislabelling
or non-identification of standard errors and standard deviations.
Our methods for imputation will be according to Chapter 6 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2019). If data are missing, we will use an available case
analysis using all data (as reported) for all randomised patients
available at the end of the study/time point of interest, regardless
of the actual treatment received. We will consider the quality of
outcome assessment as a study limitation (GRADE) and not as a
stratifying factor.
Assessment of heterogeneity
We will assess studies for clinical, statistical and methodological
heterogeneity. We will assess and quantify statistical heterogeneity
through visual inspection of the forest plots and by looking at the I2
statistic and the Chi2 test. An approximate guide to interpretation
of the I2 statistic is provided in the Cochrane Handbook for
Systematic Reviews of Interventions (Handbook 2019). An I2 value
of 50% or higher may represent substantial or considerable
heterogeneity. Where Chi2 is greater than the degrees of freedom
(K-1 degrees of freedom, where K is the number of studies), then
heterogeneity is likely to be present. We will consider heterogeneity
to be statistically significant if the P value is less than 0.10. We
will perform the meta-analysis using fixed-eEect (in the absence of
heterogeneity) and random-eEects modelling (in the presence of
heterogeneity). If there is considerable statistical heterogeneity, we
will use subgroup analyses to explore the sources.
Assessment of reporting biases
We will investigate potential publication bias and the influence of
individual studies on the overall outcome identified in this review.
We will search for and request study protocols for the included
studies and, where available, we will evaluate whether there is
evidence of selective reporting. If a meta-analysis contains at least
10 studies, we will assess publication bias using a funnel plot and
Egger's test.
Data synthesis
If more than one study is identified for a given option, and if
combining studies is appropriate, we will use RevMan 5.3 to
perform meta-analyses (RevMan 2014). We will pool data from RCTs
using a fixed-eEect model, except when heterogeneity is found.
We will pool dichotomous data using the RR measure. We will
pool continuous data using the SMD measure, if more than one
instrument is used to measure the same outcome.
We will consider the psychometric properties of outcome
instruments with regard to their suitability for pooling. For meta-
analyses on the primary outcome (tinnitus symptom severity),
whenever studies report outcomes measured using more than one
instrument, we will include data only when those instruments
are known to measure the same underlying construct of tinnitus
symptom severity (high convergent validity) and show a similar
direction of treatment-related eEect. We will take the same
approach for the secondary outcomes.
Ginkgo biloba for tinnitus (Protocol)









Cochrane Database of Systematic Reviews
Subgroup analysis and investigation of heterogeneity
If suEicient data are available, we will carry out subgroup analyses
to explore potential eEect modifiers. This will be restricted to a
very small number of subgroups. If considerable heterogeneity is
identified then we will also use these subgroup analyses to explore
sources of statistical heterogeneity.  The planned subgroups are
defined by:
• age (children < 18 years and adults ≥ 18 years);
• duration of tinnitus (acute ≤ 3 months and chronic > 3 months);
• dose of Ginkgo biloba administered;
• additional interventions (Ginkgo biloba with and without an
additional intervention);
• standardised Ginkgo biloba extracts (i.e. EGb 761) versus non-
standardised food supplement.
Sensitivity analysis
We will conduct a sensitivity analysis by excluding those studies
with a high risk of bias, thereby checking the robustness of the
conclusion from the studies included in the meta-analysis. In
addition, we will use sensitivity analyses for studies in which data
were imputed.
Summary of findings and assessment of the certainty of the
evidence
Three independent authors (MS, PS and JX) will use the GRADE
approach to rate the overall quality of evidence using GRADEpro
GDT (https://gradepro.org/). The quality of evidence reflects the
extent to which we are confident that an estimate of eEect is correct
and we will apply this in the interpretation of results. There are four
possible ratings: high, moderate, low and very low. A rating of high
quality of evidence implies that we are confident in our estimate
of eEect and that further research is very unlikely to change our
confidence in the estimate of eEect. A rating of very low quality
implies that any estimate of eEect obtained is very uncertain.
The GRADE approach rates evidence from RCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We will include a 'Summary of findings' table, constructed
according to the recommendations described in Chapter 14 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2019), for the following comparison(s):
• Ginkgo biloba versus placebo;
• Ginkgo biloba versus no intervention;
• Ginkgo biloba versus education and information only.
We will include the following outcomes in the 'Summary of findings'
table:
• tinnitus symptom severity;





• health-related quality of life;
• other adverse eEects (gastrointestinal upset, headache, allergic
reaction).
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A D D I T I O N A L   T A B L E S
 




Tinnitus Functional Index (Meikle 2012) 25 items, 8 subscales a = 0.97
Tinnitus Handicap Inventory (Newman 1996) 25 items, 3 subscales a = 0.93
Tinnitus Handicap Questionnaire (Kuk 1990) 27 items, 3 subscales a = 0.94
Table 1.   Examples of questionnaires measuring tinnitus symptom severity 
Ginkgo biloba for tinnitus (Protocol)









Cochrane Database of Systematic Reviews
Tinnitus Questionnaire (Hallam 1996) 52 items, 5 subscales a = 0.94
Tinnitus Reaction Questionnaire (Wilson 1991) 26 items, 4 subscales a = 0.96
Tinnitus Severity Scale (Sweetow 1990) 15 items Not reported
Table 1.   Examples of questionnaires measuring tinnitus symptom severity  (Continued)
 
 
A P P E N D I C E S
Appendix 1. DraL CENTRAL, MEDLINE and Embase search strategies
 
CENTRAL (CRS) MEDLINE (Ovid) Embase (Ovid)
1 MESH DESCRIPTOR Tinnitus EXPLODE ALL AND CEN-
TRAL:TARGET 602
2 (zumbido or tinnit*):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET 2283
3 MESH DESCRIPTOR Ginkgo biloba EXPLODE ALL AND
CENTRAL:TARGET 278
4 (Ginkgo* or Gingko* or Ginko* or Maidenhair):AB,EH,K-
W,KY,MC,MH,TI,TO AND CENTRAL:TARGET1127
5(Egb 761 or Egb761 or EGb-761 or GBE 761 or GBE761
or GBE-761):AB,EH,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET 226
6 (GBE50 or EGB50):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET 0
7 (rokan or tanakan or tebofortran or tebokan or
tebonin or Kavari):AB,EH,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET 51
8 (LI 1370 or LI1370 or LI-1370):AB,EH,KW,KY,M-
C,MH,TI,TO AND CENTRAL:TARGET 19
9 (flavanoid* or terpenoid* or bioflavanoid*):AB,EH,K-
W,KY,MC,MH,TI,TO AND CENTRAL:TARGET 50
10 (gingkco* or gingho* or ginosan* or bilobalid* or
tanakene or supergin*):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET12
11 (biloba):AB,EH,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET 965
12 (Eun-haeng* OR Fossil Tree* OR Ginkyo* OR Icho*
OR Ityo* OR Japanese Apricot* OR Kew Tree* OR Salis-
buria* OR Silver Apricot* OR Pterophyllus salisburiensis
OR Yinxingye* OR Prunus Ume OR Prunus mume):AB,E-
H,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET 54
13 #1 OR #2 AND CENTRAL:TARGET 2283
14 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 AND CENTRAL:TARGET 1251
15 #13 AND #14 AND CENTRAL:TARGET 86
1 exp Tinnitus/ 7718
2 (tinnit* or zumbido).ti,ab. 10914
3 1 or 2 12584
4 exp Ginkgo biloba/ 2762
5 (Ginkgo* or Gingko* or Ginko* or
Maidenhair).ab,ti. 4727
6 (Egb 761 or Egb761 or EGb-761
or GBE 761 or GBE761 or
GBE-761).ab,ti. 809
7 (GBE50 or EGB50).ab,ti. 23
8 (rokan or tanakan or tebofortran
or tebokan or tebonin or Kavar-
i).ab,ti. 121
9 (LI 1370 or LI1370 or LI-1370).ab,ti.
16
10 (flavanoid* or terpenoid* or
bioflavanoid*).ab,ti. 6066
11 (gingkco* or gingho* or ginosan*
or bilobalid* or tanakene or super-
gin*).ab,ti. 281
12 (ginkgo* or "LI 1370").nm. 2044
13 biloba.ab,ti. 3680
14 (Eun-haeng* or Fossil Tree* or
Ginkyo* or Icho* or Ityo* or Japan-
ese Apricot* or Kew Tree* or Salis-
buria* or Silver Apricot* or Ptero-
phyllus salisburiensis or Yinx-
ingye* or Prunus Ume or Prunus
mume).ab,ti. 391
15 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 or 13 or 14 12030
1 exp tinnitus/ 19134
2 (tinnit* or zumbido).ab,ti. 13886
3 1 or 2 21495
4 exp Ginkgo biloba/ 4410
5 (Ginkgo* or Gingko* or Ginko*
or Maidenhair).ab,ti. 6468
6 (Egb 761 or Egb761 or EGb-761
or GBE 761 or GBE761 or
GBE-761).ab,ti. 1073
7 (GBE50 or EGB50).ab,ti. 36
8 (rokan or tanakan or tebofor-
tran or tebokan or tebonin or
Kavari).ab,ti. 132
9 (LI 1370 or LI1370 or
LI-1370).ab,ti. 21
10 (flavanoid* or terpenoid* or
bioflavanoid*).ab,ti. 9393
11 (gingkco* or gingho* or gi-
nosan* or bilobalid* or tanakene
or supergin*).ab,ti. 376
12 biloba.ab,ti. 4941
13 (Eun-haeng* or Fossil Tree*
or Ginkyo* or Icho* or Ityo* or
Japanese Apricot* or Kew Tree*
or Salisburia* or Silver Apricot*
or Pterophyllus salisburiensis
or Yinxingye* or Prunus Ume or
Prunus mume).ab,ti. 509
14 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 or 13 18313
15 3 and 14 231
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